Here are the 10-Q quarterly reports from Pro-Dex Inc New (PDEX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PDEX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PDEX filings page.
Pro-Dex, Inc. (PDEX) reported net sales of $20.560 million for the three months ended September 30, 2026, compared with $18.530 million for the same period in 2025. Gross profit increased to $6.857 million from $5.367 million, and gross margin was 33%, compared with 29%. Operating income was $3.515 million, versus $3.109 million.
Net income was $3.048 million, compared with $4.680 million. The prior-year period included a $3.299 million unrealized gain on investments, compared with $73,000 in the current period. Operating cash flow was $6.490 million, versus $2.310 million. Backlog was approximately $43.1 million as of September 30, 2026, including $42.4 million scheduled for delivery during the remainder of fiscal 2027.
One customer accounted for 72% of quarterly sales. The exclusive supplier of a proprietary medical-grade finish for many handpiece parts told Pro-Dex shipments would resume on a timely basis by mid-November; the company said delays could put shipments to its largest customer at risk. Management said cash, cash equivalents and receivables were expected to meet requirements for at least the next 12 months.
Pro-Dex, Inc. reported strong results for the quarter ended March 31, 2026, with net sales of $19.9 million and net income of $3.9 million. Revenue rose from higher medical device sales, particularly orthopedic products for its largest customer, which represented 79% of quarterly sales. Gross margin was 31%, slightly lower than the prior year due to product mix and higher inventory-related charges. For the nine months, net sales reached $57.1 million and net income was $10.8 million, helped by gains totaling $8.1 million from the sale and milestone-related contingent value rights tied to its Monogram investment. The company acquired Advanced Precision Machining, LLC for $8.65 million to expand machining capacity and diversify into aerospace and defense, funded mainly by new term debt. Cash and cash equivalents increased to $10.0 million, working capital to $39.1 million, and backlog to about $39.0 million, while notes payable rose to $18.5 million. Pro-Dex also continued share repurchases, buying 69,422 shares for $2.8 million year-to-date.
Pro-Dex, Inc. reported higher sales and profits for the three and six months ended December 31, 2025. Quarterly net sales rose to $18.7 million from $16.8 million, while net income increased to $2.2 million, or $0.66 diluted per share, up from $0.61.
For the six-month period, net sales grew to $37.2 million from $31.7 million and net income improved to $6.9 million, or $2.07 diluted per share, versus $1.33. Growth was driven mainly by orthopedic device sales tied to a next-generation handpiece for the company’s largest customer and stronger CMF driver demand, partially offset by lower repair revenue.
Pro-Dex realized $8.9 million of cash proceeds from the sale of Monogram Technologies shares and recorded a $6.8 million realized gain, contributing to stronger cash flow and lifting cash and cash equivalents to $8.0 million. Total notes payable fell to $10.5 million. Customer concentration remains high, with one customer representing about 79% of sales and 82% of accounts receivable, and order backlog was approximately $37.4 million.
Pro-Dex, Inc. reported stronger quarterly results. Net sales were $18.53 million, up 24% year over year, as orthopedic product shipments recovered and CMF drivers grew. Gross margin was 29% versus 35% a year ago, reflecting higher product costs, under‑absorption, and lower repair margins.
Operating income was $3.11 million. Other income rose to $3.11 million, including $3.30 million of unrealized gains on investments. Net income was $4.68 million, with diluted EPS of $1.40. Cash was $0.51 million and investments measured at fair value totaled $10.19 million. Working capital was $37.12 million. Notes payable were $13.28 million, and $2.16 million was drawn on the revolving loan.
Backlog was approximately $46.8 million, with $43.6 million scheduled for delivery during the remainder of fiscal 2026. Customer concentration remained high: one customer represented 78% of revenue and 84% of gross receivables. After quarter‑end, Pro-Dex received $8.9 million in cash from the Monogram sale and expects to record a $6.8 million realized gain in the next quarter; it also received contingent value rights tied to future milestones.